|
|
Vaccine Detail
|
KSA-KLH Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: KSA-KLH Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007630
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: Ep-CAM
- EPCAM
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A peptide vaccine containing an epitope of human tumor-associated KSA antigen (Ep-CAM) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. KSA antigen, a type-I transmembrane glycoprotein and a cellular adhesion molecule with a molecular mass of 40 kDa, is overexpressed on the majority of epithelial tumor cells. KSA antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with KSA-KLH may result in the production of antibodies as well as eliciting a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the KSA antigen. (NCIT_C2520).
|
| Host Response |
|
|
| References |
NCIT_C2520: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2520]
|
|
